OFK Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Orion Corporation News
OFK FAQ
What was Orion Corporation’s price range in the past 12 months?
Currently, no data Available
What is Orion Corporation’s market cap?
Orion Corporation’s market cap is CHF10.25B.
When is Orion Corporation’s upcoming earnings report date?
Orion Corporation’s upcoming earnings report date is Oct 28, 2026 which is in 93 days.
How were Orion Corporation’s earnings last quarter?
Orion Corporation released its earnings results on Jul 17, 2026. The company reported $0.924 earnings per share for the quarter, beating the consensus estimate of $0.882 by $0.042.
Is Orion Corporation overvalued?
According to Wall Street analysts Orion Corporation’s price is currently Undervalued.
Does Orion Corporation pay dividends?
Orion Corporation does not currently pay dividends.
What is Orion Corporation’s EPS estimate?
Orion Corporation’s EPS estimate is 1.06.
How many shares outstanding does Orion Corporation have?
Currently, no data Available
What happened to Orion Corporation’s price movement after its last earnings report?
Orion Corporation reported an EPS of $0.924 in its last earnings report, beating expectations of $0.882. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Orion Corporation?
Currently, no hedge funds are holding shares in CH:OFK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orion Corporation
Orion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.
OFK Stock 12 Month Forecast
Average Price Target
$66.93







